Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

20062,618 citationsJournal Articlebronze Open Access

Authors

Deborah K. Armstrong

Brian N. Bundy

Lari Wenzel · University of California, Irvine

Helen Huang

Rebecca N. Baergen · NewYork–Presbyterian Hospital

Shashikant Lele

Larry J. Copeland · The Ohio State University

Joan L. Walker · University of Oklahoma

Robert A. Burger

Abstract

As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Endometrial and Cervical Cancer Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 1, pp. 34-43

DOI: 10.1056/nejmoa052985

Field-Weighted Citation Impact: 191.22